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Summary 
 
Pathogenic variants in over 1,000 genes are already known to cause diverse 
developmental disorders (DDs) as a result of perturbed embryonic and fetal 
development, and yet the high prevalence of undiagnosed patients suggests that 
many more genetic causes remain undiscovered. We studied 1,133 children with 
severe, undiagnosed DDs, and their parents, using a combination of genome-wide 
assays to detect all major classes of genetic variation in the protein-coding portion of 
the genome. In addition to the 28% of children with pathogenic variants, 
predominantly de novo mutations, in 148 genes already robustly associated with 
DDs, we present compelling evidence for 12 recurrently mutated novel genes 
causing DDs in 35 individuals. Clustering of missense mutations in six of these new 
genes suggest an activating or dominant negative mechanism. Simulation studies 
and modelling of 32 candidate novel genes in zebrafish strongly suggest that many 
more novel genetic causes of DDs await discovery and that a genotype-driven 
strategy to finding them is likely to prove highly productive. 
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Introduction 
 
Despite three decades of successful, predominantly phenotype-driven, discovery of 
the genetic causes of monogenic disorders 1, up to half of children with severe 
developmental disorders of likely genetic origin remain without a genetic diagnosis. 
Especially challenging are those disorders rare enough to have eluded recognition as 
a discrete clinical entity, those whose clinical manifestations are highly variable, and 
those that are difficult to distinguish from other, very similar, disorders. 
 
An alternative method of discovering novel genes underlying developmental 
disorders is suggested by the success in the past decade of discovering pathogenic 
chromosomal deletions and duplications across a broad range of developmental 
abnormalities, including both neurodevelopmental disorders and congenital 
malformations of different organ systems. This genotype-driven approach applies 
genome-wide discovery of genetic variation in large numbers of patients with 
diverse developmental abnormalities to identify small subsets of patients with 
similar pathogenic variants. This strategy has identified new disorders that could not 
be defined on a phenotypic basis alone 2 and expanded the phenotypic range 
associated with variants that had been initially discovered by focusing on patients 
with highly similar clinical features (e.g. 3,4). The analysis of parent-offspring trios, 
which greatly facilitates the identification of de novo mutations, has catalyzed these 
discoveries.  
 
More recently, exome sequencing of tens to hundreds of parent-offspring trios has 
highlighted the role of de novo mutations in protein-coding exons in intellectual 
disability, autism, schizophrenia, epilepsy and congenital heart defects 5-13. Some of 
these papers have focused on diagnostic analyses of pathogenic de novo mutations 
in known disease-associated genes, while others have highlighted particular 
pathways enriched for pathogenic mutations, but none have achieved robust 
genome-wide discovery of novel genes underlying these disorders. Only with 
subsequent resequencing of plausible candidate genes in many additional patients 
has conclusive discovery of novel genes in these disorders been achieved 6,14 . We 
hypothesised that increasing the sample size of exome sequencing to over 1,000 
trios with severe, undiagnosed developmental disorders should: (i) allow the 
conclusive genome-wide discovery of novel disease genes, (ii) broaden the 
phenotype-genotype correlation associated with known disease genes and (iii) 
enable the relative contribution of different classes of genetic variants to be 
quantified. 
 
We have established a UK-wide network to recruit patients with diverse, severe 
undiagnosed developmental disorders, dominated by, but not limited to, 
neurodevelopmental disorders, through the 24 regional genetics services of the UK 
National Health Service (NHS) and Republic of Ireland. Here we describe the detailed 
analysis of 1,133 parent-offspring trios using a combination of exome sequencing, 
genome-wide SNP genotyping and exon-resolution detection of deletions and 
duplications using array comparative genomic hybridization (exome-aCGH), which 
has led to the conclusive identification of 12 novel disease genes and suggestive 
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evidence for a further 6 plausible disease genes for which more evidence is required 
to support their pathogenic role. We also present the results of zebrafish knockdown 
models for 32 genes, which as a set showed a striking enrichment for developmental 
defects compared to randomly knocked-out genes in zebrafish. 
 
Summary of the phenotypic and genotypic data 
The median age at last clinical consultation of these 1,133 children was 5.5 (age 
distribution shown in Extended Data Fig. 1). All children were phenotyped by clinical 
geneticists using the Human Phenotype Ontology (HPO). The median number of HPO 
terms used to describe the child’s clinical features was 6, and ranged from 1 to 27, 
reflecting the mix of both generic and highly specific clinical presentations (Extended 
Data Fig. 2, Supplementary Table 1). Among the most common phenotypes were 
intellectual disability or developmental delay (87% of children), abnormalities 
revealed by cranial MRI (30%), and seizures (24%). As expected, the most common 
non-brain malformation was congenital heart defects (11%). Relevant family history, 
pertinent pregnancy and neonatal parameters, developmental milestones, and 
measurements of height, weight and head circumference were also recorded.  
 
Most (849/1,101) families were sporadic (the child is the only affected family 
member), but 111 children had one or more parents with a developmental disorder 
that might share the same underlying genetic cause, and 124 had a similarly affected 
sibling (Extended Data Table 1). 
 
We anticipated that prior clinical genetic testing would have diagnosed a high 
proportion of children with large, pathogenic CNVs, as well as those with canonical 
presentations of well-recognised genetic syndromes, thus enriching this research 
cohort of undiagnosed children for genetic causes of less well-recognised known 
syndromes as well as novel genetic disorders. 
 
We exome sequenced 1,133 affected children and their parents, from 1,101 families, 
representing 1,071 unrelated children and 30 sibships. We also performed exome-
aCGH on the children and genome-wide SNP genotyping on the children and their 
parents to enable analyses of deletions, duplications, uniparental disomy (UPD) and 
mosaic large chromosome rearrangements. After quality control, we obtained high 
quality exome-aCGH data on 1,009 children, and SNP genotyping data on 1,006 
families. 
 
We called single nucleotide variants (SNVs), insertion deletion events (indels), copy 
number variants (CNVs) and UPD from the exome data (Methods). We identified 
candidate de novo SNVs and indels for independent validation (Methods). We also 
detected CNVs from the exome-aCGH data and we inferred CNV inheritance and 
discovered UPD and mosaic large chromosomal rearrangements from SNP 
genotyping data. The SNVs, indels and CNVs were analysed jointly in the following 
analyses, allowing, for example, the identification of compound heterozygous CNVs 
and SNVs affecting the same gene. 
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The genetic ancestry of these children, is representative of the clinical population at 
need of diagnosis in the UK, being predominantly (~90%) of Northwest European 
ancestry (Extended Data Fig. 3). 51 children (4.5%) were from self-declared 
consanguineous unions, although a genetic analysis of parental kinship provided a 
more accurate picture of consanguinity, with 47 pairs of parents (4.1%) exhibiting 
kinship equivalent to, or in excess of second cousins, of which 33 were also self-
declared consanguineous (Extended Data Table 2, Extended Data Fig. 4). The 
increased prevalence of (presumably recessive) developmental disorders as a result 
of parental relatedness is well attested 15, 
 
In addition to the genetic data generated on these families with developmental 
disorders, to empower our analysis of exon-resolution deletions and duplications, 
we also performed exome-aCGH on 1,013 UK controls from the Scottish Family 
Health Study 16,17 and the UK Blood Service collection 18 (Methods). 
 
From our exome sequencing and exome-aCGH data, we detected an average of 
19,811 coding or splicing SNVs, 491 coding or splicing indels and 148 CNVs per child. 
From analyses of the SNP genotyping data 19 we identified 6 children with UPD and 5 
children with mosaic large chromosomal rearrangements. 
 
We identified 1,618 de novo variants (1,417 SNVs, 114 indels and 87 CNVs) in coding 
and non-coding regions, Supplementary Tables 2 and 3), of which 1,596 (98.6%) 
were validated using a second, independent assay, and the remainder were 
validated clinically. This represents an average of 1.12 de novo SNVs and 0.09 de 
novo indels in coding or splicing regions per child, which is within the range of 
previous, smaller, studies of children with developmental disorders 5-13, but slightly 
higher than most. The distribution of de novo SNVs and indels per child ranged from 
0-7, and very closely approximated the Poisson distribution expected for random 
mutational events with little variation in mutation rate across children (Extended 
Data Fig. 5). These data rule out germline mutator phenotypes (greater than ten-fold 
increased mutation rate) in our patients, and we conclude that such mutator 
phenotypes, if indeed they exist, can only very rarely be a cause of developmental 
disorders. 
 
Analysis of known causes of developmental disorders 
To identify novel genetic causes of developmental disorders in these 1,133 children 
we must first identify children with pathogenic variants in genes that have been 
robustly associated with DD.  We identified 28% (N=317) of these children with likely 
pathogenic variants (details in Supplementary Table 4 and ref 20) in 1,142 known 
(published before Nov 2013) developmental disorder genes (24.3%), or with large 
deletions or duplications that encompass many genes (3.7%). The majority of these 
diagnoses involved de novo SNVs, indels or CNVs (Table 1). The single-gene 
diagnoses were distributed among 148 different genes, most of which (95/148) were 
only observed once in the 1,133 trios (Extended Data Figure 6). A handful of known, 
more mutable, haploinsufficient DD genes (e.g. ARID1B, SATB2, SYNGAP1, ANKRD11, 
SCN1A, DYRK1A, STXBP1, MED13L), each account for 0.5-1% of children in our 
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cohort. For 17 of these children (5% of diagnosed children) we identified two 
different genes with pathogenic variants, suggesting that some children with DD 
remain undiagnosed because they have two or more genetic disorders that result in 
a composite clinical phenotype that does not closely resemble a known condition.  
One example of this is a child with maternal uniparental disomy of chromosome 14 
that likely accounts for her truncal obesity, short stature and intellectual disability, 
and a compound heterozygous pair of damaging variants in TECTA, on chromosome 
11, which likely accounts for her hearing loss. 
 
The diagnostic yield was higher in females (30.4%) than males (25.9%), which was 
largely due to an increased yield of diagnostic de novo mutations in females (Table 
1). Although some of this effect was accounted for by de novo mutations in X-linked 
dominant genes due to the higher mutation rate of the paternally-inherited X 
chromosome, females also had a significantly higher diagnostic yield of autosomal de 
novo mutations (p=0.01, Fisher exact test). Larger sample sizes will be required to 
investigate more deeply whether there are substantive differences in genetic 
architecture between male and female children, as has been suggested for autism 21.  
 
In addition to enriching for novel genetic causes of DD, this analysis of known 
genetic causes of DD in these children highlighted the high genetic heterogeneity in 
this research cohort, and suggested that the vast majority of novel genetic causes of 
DD observed recurrently among these 1,101 families would be de novo mutations in 
autosomal dominant or X-linked genes. 
 
Burden analyses of classes of potentially pathogenic variants 
Analyses that quantify and assess the significance of the enrichment in cases relative 
to controls (or null expectation) of a particular class of variation, so-called ‘burden 
analyses’, are highly informative for: (i) highlighting a particular class of variant as 
deserving of more detailed analysis, and (ii) estimating what proportion of a 
particular class of variant is likely to be pathogenic. For example, the observation of 
an enrichment of de novo deletions and duplications in children with autism 22 
catalysed intensive investigation of de novo deletions across a broad range of 
neurodevelopmental disorders. However, not all of these de novo deletions are 
pathogenic, as evidenced by the presence of such events in 1-2% of children without 
apparent developmental disorders 23. 
 
We observed a burden of de novo CNVs in the 1,133 trios, despite the fact that 77% 
of them had previously been screened for pathogenic CNVs using a lower resolution 
clinical microarray (we observed 87 in 1,133 proband trios versus 12 in 416 control 
trios from the Scottish Family Health Study, p-value: 0.0004). As expected, we 
observed a considerably lower burden of large CNVs in patients who had previously 
had clinical microarray testing (Extended Data Figure 7). 
 
To evaluate the role of de novo SNVs and indels in causing DD, we first established a 
null expectation for the number of mutations of different functional consequences 
expected in every gene in the genome, by scaling gene-specific mutation rates that 
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account for gene length and sequence context 24 by the number of trios analysed 
(Methods). We then compared the observed number of protein-altering de novo 
SNVs and indels in known DD genes of different types to this null expectation. We 
observed no significant excess of any functional class of de novo SNVs or indels in 
autosomal recessive DD genes (Figure 1A). This suggests that only a small minority, if 
any, of the de novo mutations we observed in these genes are likely to be in trans to 
another damaging mutation, and thus causing the disorder observed in the child due 
to biallelic disruption of a gene. By contrast, we observed a highly significant excess 
of all ‘functional’ (coding and splice site variants excepting synonymous changes) 
classes of de novo SNVs and indels in dominant and X-linked DD genes (Figure 1B), 
within which de novo mutations can be sufficient to cause disease.  Not all protein-
altering mutations in known dominant and X-linked DD genes will be pathogenic, 
and these burden analyses can guide estimates of positive predictive values for 
different classes of mutations in known DD genes. The remaining, non-DD, genes in 
the genome also exhibit a more modest, but still significant, excess of functional, but 
not silent, de novo SNVs and indels (Figure 1C).  
 
We compared the observed number of genes recurrently mutated with functional 
SNVs and indels in unrelated individuals with simulations derived from the mutation 
rate of every gene (Methods). We observed 96 such recurrently mutated genes, 
which represents a highly significant excess of 41 genes more than the median 
number (56) expected by chance from simulations (Figure 2A). This enrichment is 
even more pronounced (observed:29,  expected:3) for genes with recurrent LoF 
mutations (Figure 2B). If we focus only on the de novo mutations in undiagnosed 
individuals we observe an excess of 22 (observed: 45, expected: 23) recurrently 
mutated genes with functional mutations (Figure 2A), and an excess of 8 
(observed:9, expected:1) recurrently mutated genes with LoF mutations (Figure 2B). 
This significant excess of recurrently mutated genes in undiagnosed individuals 
strongly suggests that an appreciable fraction, but by no means all, of these 
recurrently mutated genes are novel DD genes.  
 
We also included 7,237 annotated regulatory sequences in our custom exome 
design, comprising validated enhancers 25, the most highly conserved non-coding 
elements in the genome 26, and likely enhancers identified from chromatin 
immunoprecipitation experiments 27 (Methods). We validated 74 de novo SNVs and 
indels in these regulatory sequences. This number of de novo mutations is consistent 
with the null expectation given the size of the mutational target that these 
regulatory sequences represent (p>0.05). Compared to other sites in these targeted 
regulatory sequences these de novo mutations were not enriched for highly 
conserved sites (p>0.05). Moreover, we did not observe a significant excess of 
recurrently mutated regulatory sequences.  
 
We next evaluated a possible excess of potentially pathogenic inherited SNVs in our 
probands. In contrast to the de novo analyses described above, which use expected 
mutation rates to evaluate significance, we require a control group to compare 
against, so we constructed a set of “untransmitted diplotypes”, corresponding to the 
pair of untransmitted haplotypes for each trio at every position in the genome 
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(Methods). This analytical strategy has the advantage of being robust to population 
structure. We first considered very rare (MAF < 0.0005%) inherited LoF variants, and 
observed a genome-wide trend towards over-transmission to probands (p=0.015). 
By contrast, very rare damaging (predicted damaging by both SIFT and PolyPhen) 
missense variants showed no such excess. We next evaluated biallelic (homozygous 
and compound heterozygous) LoF variants with minor allele frequency below 5% 
(Supplementary Table 5), and observed a 0.56-fold depletion of such variants 
(p=0.04) in probands with a likely dominant cause of their disorder (either a 
diagnostic de novo mutation or an affected parent) compared to other probands. 
Again we saw no enrichment in biallelic damaging missense variants (Extended Data 
Table 3), consistent with a similar observation in children with autism 28. We looked 
specifically for enrichment in the list of 1,142 known DD genes, and saw stronger 
enrichment (Supplementary Table 5) than genome-wide, but we still observed 1 
biallelic and 34 monoallelic rare LoF SNVs in the untransmitted diplotypes. These 
data suggest it is incorrect to assume that any damaging variants in known DD genes 
discovered in DD patients are certain to be pathogenic. These observations also 
imply that although inherited LoF variants (both monoallelic and biallelic) are likely 
contributing to DD in our patients, much larger sample sizes will be required to 
pinpoint specific DD genes in this way. 
Novel developmental disorder genes  
To identify genes that were enriched in damaging de novo mutations, we applied 
two statistical tests for every gene (Methods): first we tested for an overabundance 
of de novo LoF mutations in each gene, and second we tested for an overabundance 
of functional de novo mutations that are clustered within the coding sequence of 
each gene (as dominant negative or activating missense variants that are often 
clustered in this manner). We applied these two tests to all de novo mutations 
observed in 1,130 DDD children (removing one twin from each of 3 identical twin-
pairs). Moreover, to increase power to detect DD genes, we also meta-analysed our 
data with de novo mutations observed in 2,347 published trios with developmental 
disorders which show etiological overlap with the patients studied here (we term 
this the meta-DD dataset). These include neurodevelopmental disorders such as 
intellectual disability 6,11, epileptic encephalopathy 5, autism 8-10,12 and schizophrenia 
7, as well as congenital heart defects 13. Figure 3 shows a comparison of the 
statistical evidence for an enrichment of LoF and functional de novo mutations in the 
DDD and meta-DD datasets. These analyses successfully identify 20 known DD genes 
at genome-wide significance (p < 1.31x10-6, a Bonferroni p value of 0.05 corrected 
for 38,504 tests [Methods]). Despite the broad phenotypic ascertainment in our data 
and the meta-analysed datasets, we can detect developmental disorder genes on 
statistical grounds alone, without incorporating considerations of phenotypic 
similarity or functional plausibility. 
 
The most significantly mutated gene is the DDD dataset is ARID1B, with 11 
independent LoF mutations. Also of note is PACS1 with four identical missense 
mutations (which is the same mutation described previously in two similar 
patients 29). The high statistical significance of PACS1, despite it having fewer 
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mutations than several other genes with similar mutation rates, is strengthened by 
the clustering of mutations within the gene.  
 
For some known DD genes, our data increase significantly the number of patients 
with mutations in a specific gene, and thus allow a fuller characterization of the 
phenotype associated with mutations in that gene. For example, the six patients 
with MED13L mutations represent double the number of patients previously 
described with mutations in this gene and are the first reported single base 
mutations, with the previously described patients all having large structural 
rearrangements 30. MED13L lies within a gene desert that contains many highly 
conserved non-coding sequences and is flanked by TBX5, a gene known to be critical 
in cardiac development  31. In contrast to the previously reported patients, none of 
the six patients identified here are known to have congenital heart defects, 
potentially suggesting that larger variants might be perturbing the regulatory 
landscape in addition to truncating the gene.  
 
We repeated the analysis of gene-specific enrichment for mutations described 
above, but excluding the 317 individuals with a known cause of their developmental 
disorder (as described above) in order to increase our power to detect novel DD 
genes. In this analysis the genetic data were integrated with phenotypic similarity of 
patients with mutations in the same gene, available data on model organisms and 
functional plausibility. We identified 12 novel disease genes with compelling 
evidence for pathogenicity (Table 2). The statistical test for mutation enrichment 
exceeds the genome-wide significance threshold of 1.36x10-6 in 9/12 of these 
(Methods), with the remaining three genes (PCGF2, DNM1 and TRIO) lying just below 
this significance threshold. The two children with identical Pro65Leu mutations in 
PCGF2, which encodes a component of a Polycomb transcriptional repressor 
complex, share a strikingly similar facial appearance representing a novel and 
distinct dysmorphic syndrome. DNM1 was previously identified as a candidate gene 
for epileptic encephalopathy (EE) 5. Two of the three children we identified with 
DNM1 mutations also had seizures, and a heterozygous mouse mutant has seizures 
32. Cumulatively the evidence strongly points to DNM1 being a novel gene for EE. In 
the case of TRIO, in addition to two de novo missense SNVs, we identified an 
intragenic de novo 82kb deletion of 16 exons of TRIO. De novo intragenic deletions 
are rarer than smaller de novo LoF variants (SNVs and indels) in our cohort, and thus 
this observation adds considerable additional genetic evidence to the pathogenicity 
of mutations in TRIO. 
 
One striking observation among the novel disease genes is that for four genes 
(PCGF2, COL4A3BP, PPP2R1A and PPP2R5D), like PACS1, we observed identical 
missense mutations in unrelated, phenotypically similar, patients (Figure 4). We 
hypothesise that the mutations in these four genes are operating by either dominant 
negative or activating mechanisms. For a fifth gene, BCL11A, we identified highly 
significant clustering of non-identical missense mutations.  
 
The three individuals with de novo mutations in COL4A3BP have identical Ser132Leu 
mutations in the encoded protein, an intracellular transporter of ceramide. 
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Phosphorylation of this specific serine residue has previously been shown in 
mutagenesis studies to down-regulate transporter activity from the ER to the golgi 33  
and this mutation is predicted to abrogate this regulation, presumably resulting in 
intra-cellular imbalances in ceramide and its downstream metabolic pathways. 
 
Of the three individuals with de novo mutations in PPP2R1A, two have identical 
Arg182Trp mutations and one has a nearby Pro179Leu mutation. PPP2R1A encodes 
the constant scaffolding A subunit of the Protein Phosphatase 2 complex, which also 
comprises a constant catalytic C subunit and a variable regulatory B subunit. 
Precisely these two amino acids have been previously identified as sites of driver 
mutations in endometrial and ovarian cancer, and mutagenesis studies have shown 
that mutating either of these two residues in one of the 15 HEAT domains of this 
protein results in impaired binding of B subunits 34 . 
 
Three of the four individuals with de novo mutations in PPP2R5D have identical 
Glu198Lys mutations in the B56 domain of the encoded protein, and the other 
individual has a nearby Pro201Arg mutation. Intriguingly, PPP2R5D encodes one of 
the possible B subunits of the same Protein Phosphatase 2 complex described above. 
The tight clustering of mutations in PPP5RD suggest a similar mechanism of 
perturbing interactions between subunits of this complex, although further 
functional studies will be required to confirm this hypothesis. 
 
Three individuals have non-identical but clustered mutations in BCL11A (Thr47Pro, 
Cys48Phe and His66Gln), which encodes a newly recognized member of SWI-SNF 
complex 35 . Many other genes (e.g. SMARCA2, ARID1B) that encode members of the 
same complex are known dominant DD genes. The clustering of mutations is 
suggestive of a gain-of-function mechanism. Some of the other known DD genes in 
this complex are haploinsufficient (e.g. ARID1B), but others operate by a gain-of-
function mechanism (e.g. SMARCA2). This key chromatin modifying complex is a 
hotspot for dominant DD genes, and it is noteworthy that we also observed two de 
novo mutations (1 LoF, 1 missense) in SMARCD1, which encodes another member of 
this complex, although this does not yet represent sufficiently compelling evidence 
to declare it a novel DD gene. 
 
For several of these novel DD genes, the meta-analysis integrating published data 
increased the significance of enrichment. For example, a total of five de novo LoF 
variants in POGZ were identified, two from our cohort, two from recent autism 
studies and one from a recent schizophrenia study.  
 
Six genes had suggestive statistical evidence of being novel DD genes, defined as 
being a p value for mutation enrichment less than 1x10-4 and being plausible from a 
functional perspective. NAA10 is already known to cause an X-linked recessive 
developmental disorder in males 36, but here we identified missense mutations in 
females, suggesting a different, X-linked dominant, disorder. We expect that the 
majority of these genes will eventually accrue sufficient evidence to meet the 
stringent criteria we defined above for declaring a novel DD gene (Table 3). 
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We did not attempt an analogous statistical analyses of genes enriched for candidate 
pathogenic variants under other genetic models (e.g. X-linked, autosomal recessive) 
as our initial burden analyses suggested that these analyses would be severely 
under-powered in an analysis of 1,130 patients. 
 
Assessment of candidate genes in animal models 
 
To help direct future, deeper, functional experiments on the non-redundant role 
during development of candidate genes from this study we used two approaches.  
First, morphant-induced phenotypes were recorded in the first 5 days of zebrafish 
development.  Second we performed a systematic review of perturbed gene 
function in human, mouse, xenopus, zebrafish and drosophila.  In both approaches 
the animal phenotypes were compared to those seen in individuals in our cohort  
 
We undertook an antisense-based loss of function screen in zebrafish to assess 32 
candidate DD genes with de novo LoF, de novo missense or biallelic LoF variants from 
exome sequencing (Methods and Supplementary Data Table 6). The 32 human 
candidate genes corresponded to 39 zebrafish orthologues. Knockdowns of these 
zebrafish genes were repeated at least twice and all morpholinos were co-injected 
with tp53 morpholino to eliminate off-target toxicity. Successful knockdown of 
the targeted mRNA could be confirmed using RT-PCR for 82.4% of genes (28/34) and 
9/11 (82%) of genes that were tested gave an equivalent phenotype when knocked 
down by a second, independent morpholino. Knock-down of at least one or a pair of 
zebrafish orthologues of 65.6% of candidate DD genes (21 out of 32) resulted in 
perturbed embryonic and larval development (Table 4, Figure 5, Extended Data 
Figure 8 and Supplementary Data Table 7). A recent large scale Zebrafish 
mutagenesis study of 1,216 randomly selected genes found that only 6% give 
homozygous mutant phenotypes during the same stages of development 37, while a 
morpholino based screen of 150 selected genes encoding co-translationally 
translocated (CTT) proteins gave a 12% frequency of developmental phenotypes 38, 
suggesting at least a five-fold enrichment of developmentally non-redundant genes 
among the 32 selected for modelling.  We then compared the phenotypes of the 
zebrafish morphants to those of the DDD individuals with de novo mutations or 
biallelic LoF variants in the orthologous genes (Table 4). 11/21 (52.4%) of the genes 
were categorised as strong candidates based on phenotypic similarity (Figure 5A).  
7/11 were potential microcephaly genes whose gene knockdown in zebrafish gives 
significant reductions in both head measurements, and neural tissue (Figure 5B, 
Methods).  6/21 (28.6%) genes resulted in severe morphant phenotypes which could 
not be meaningfully linked to patient phenotypes. As many of our candidate DD 
genes carried heterozygous LoF variants (de novo mutations), it is to be expected 
that the severity of LoF phenotypes in zebrafish may exceed that observed in our 
patient cohort.  In some cases, antisense dosage adjustments helped to strengthen 
the phenotypic concordance between model and patient (e.g. ETF1, PSD2). The 
genes with proven non-redundant developmental roles can reasonably be assigned 
higher priority for downstream functional investigations and genetic analyses (e.g. 
replication studies). 
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Our systematic review of gene perturbation in multiple species sought both 
confirmatory and contradictory (e.g. homozygous knock-out mutant is healthy) 
evidence from other animal models for these 21 apparently developmentally 
important genes. We identified 16 genes with solely confirmatory data, often from 
multiple different organisms, none with solely contradictory data, two with both 
confirmatory and contradictory evidence and three with no evidence either way 
(Extended Data Table 4). 
 
Discussion 
 
Our patient cohort was selected for severe or extreme developmental phenotypes 
presenting early in life and presumed likely to be genetic in origin for which a 
diagnosis had not proved possible using routinely available clinical investigations. 
Despite the broad clinical ascertainment of our patient cohort, and their likely 
genetic heterogeneity, through analysis of 1,133 parent-offspring trios we 
discovered 12 novel DD genes (and re-discovered many known DD genes) simply by 
virtue of these genes being highly significantly enriched for damaging de novo 
mutations. These results validate our genotype-driven strategy as complementary to 
the traditional phenotypic-driven strategy of selecting patients with specific clinical 
features for detailed study, and offers a productive avenue for the discovery of novel 
developmental disorders that result in highly variable or indistinct clinical 
presentations. 
 
Our meta-analysis with previously published studies of developmental disorders 
allowed us to increase power to detect novel DD genes. These discoveries highlight 
the common genetic etiologies that exist between diverse neurodevelopmental 
disorders such as intellectual disability, epilepsy, autism and schizophrenia. These 
observations bolster previous observations based on large deletions and duplications 
shared between different neurodevelopmental disorders 39. 
 
Adding the patients with pathogenic mutations in the 12 novel DD gene we 
discovered to those with pathogenic mutations in known DD genes increased the 
diagnostic yield from 28% to 31%. What, then, are the causes of the developmental 
disorders in the other 69% of patients? There are no obvious indications (e.g. fewer 
phenotype terms, older age of recruitment) that the undiagnosed patients are any 
less severely affected than the diagnosed patients. We anticipate that there are 
many more pathogenic, monogenic, coding mutations in these undiagnosed patients 
that we have detected, but for which compelling statistical evidence is lacking. 
Evidence supporting this comes from the significant enrichment in undiagnosed 
patients of functional mutations in genes predicted to exhibit haploinsufficiency 
(Extended Data Fig. 9), as well as the strong enrichment for developmental 
phenotypes in the zebrafish knock-down screen.  
 
Our study of just over 1,000 trios has only 5-10% power to detect an averagely 
mutable haploinsufficient gene (Figure 6), whereas, studying 10,000 trios would 
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provide greater than 90% power to detect most haploinsufficient DD genes. In 
accordance with this modeling, the known DD genes that we have re-discovered in 
our analyses are greatly enriched for more mutable, longer, genes, for which we 
would expect to have most statistical power to detect a significant enrichment of 
damaging mutations. As the mutational target of haploinsufficient genes is 
significantly larger than that for the typically more localized mutations that act by 
dominant negative or activating mechanisms, we think it is reasonable to extrapolate 
that the discovery of such pathogenic mechanisms is even further from saturation 
than for haploinsufficient genes. Moreover, in contrast to our success with 
identifying novel dominant DD genes, we were unable to identify any novel recessive 
DD genes with compelling statistical evidence.  
 
Taken together, and provided some necessary modeling assumptions 
(Supplementary Information), these considerations suggest that analysing 10,000 
trios (from a largely outbred population such as the one studied here) should enable 
the discovery of most haploinsufficient genes causing DDs, but that studying well in 
excess of 10,000 trios will be required to detect most autosomal recessive causes of 
developmental disorders. These analyses motivate the global sharing of minimal 
genotypic and phenotypic data, such as through the DECIPHER web portal 40, to 
provide diagnoses for patients who would otherwise remain undiagnosed. Plausibly 
pathogenic de novo SNVs, indels and CNVs, and biallelic LoF variants in genes not yet 
associated with disease, observed in undiagnosed patients in our cohort are shared 
through DECIPHER (http://decipher.sanger.ac.uk).  
 
We identified significant differences in the genetic architecture of developmental 
disorders between male and female probands, but not between major phenotype 
subgroups. The increased burden of monogenic disease among females with 
neurodevelopmental disorders has only recently started to become more apparent 
21,41, and our observations strengthen this proposition. The predicted corollary is that 
male probands might be enriched for poly/oligogenic causation; however, testing 
this hypothesis will require further investigation in larger cohorts. 
 
Given our limited power to detect pathogenic mutations that act through dominant 
negative or activating mechanisms, it was notable that in four of our novel genes 
(COL4A3BP, PPP2R1A, PPP2R5D and PCGF2) we observed identical de novo 
mutations in unrelated trios. Two hypotheses might explain this observation: first, 
that there is a vast number of different gain-of-function mutations in the human 
genome, of which we are just scratching the surface in this study, or second, that 
these particular variants are enriched in our cohort due to these mutations 
conferring a positive selective advantage in the germline 42. Analysis of larger 
datasets will be required to distinguish between these hypotheses, although they 
are not necessarily mutually exclusive. 
 
While we have adopted a predominantly statistical approach to discovering novel DD 
genes, for some genes it has also proven valuable to take into consideration the 
phenotypic similarity between patients sharing similar mutations relative to the 
broader set of patients (e.g. PCGF2), as well as functional data on individual variants 
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or genes (e.g. COL4A3BP). While it is difficult to quantify probabilistically these 
phenotypic and functional sources of evidence, used judiciously in tandem with 
strong statistical genetics support, these sources of evidence can add value to 
genotype-driven analyses. 
 
Our study of developmental disorders shares both methodological and biological 
similarities with a recent meta-analysis of somatically mutated ‘driver’ genes in 
cancer 43. The 262 cancer driver genes identified in that study exhibit a highly 
significant four-fold enrichment for known DD genes. In keeping with this 
observation 3/12 of the novel DD genes identified in this study are also among those 
262 cancer driver genes. This sharing of variants, genes and pathways between 
cancer and embryonic development leads to both concerns and opportunities: 
concerns about the potential for an elevated risk of cancer among children with 
these specific developmental disorders, although the overlap between variants 
observed somatically and in the germline can be minimal  44, and opportunities to 
accelerate developing therapies for rare developmental disorders by leveraging 
advances and investments in cancer drug development. 
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Methods Summary 
 
1,133 patients with severe, undiagnosed, developmental disorders and their parents 
were recruited and systematically phenotyped at 24 clinical genetics centres within 
the UK National Health Service and the Republic of Ireland. Patient and parental 
saliva or blood-extracted DNAs were assayed with a bespoke Illumina ArrayExpress 
genotyping array and customized Agilent SureSelect exome sequencing targeting 
additional non-coding regulatory sequences. Patients were also assayed with two 
Agilent one-million probe Comparative Genomic Hybridisation arrays (aCGH) that 
collectively targeted almost all coding exons as well as a genome-wide backbone of 
non-coding sites. Variants were called from exome sequencing using SAMtools, 
GATK, Dindel and an in-house CNV calling algorithm, CoNVeX. De novo SNV and indel 
mutations were detected using the DeNovoGear software 45. Deletions and 
duplications were called from aCGH using an in-house algorithm, CNsolidate. 
Putative de novo SNVs and indels were validated using capillary sequencing and de 
novo CNVs validated using a variety of independent methods. Variants were 
annotated with their likely functional impact using the Ensembl Variant Effect 
Predictor (Supplementary Information). Diagnostic pathogenic variants were 
identified by clinical review of candidate variants flagged by applying Mendelian 
inheritance rules to a clinically-curated list of genes known to cause developmental 
disorders (DDG2P, available at http://decipher.sanger.ac.uk/ddd#ddgenes). Gene-
specific rates for different functional classes of mutation that account for the length 
and sequence context of the gene 24 were used to estimate: (i) the expected number 
of mutations in 1,133 trios in each gene, (ii) the expected number of mutations in 
sets of genes and (iii) the expected number of recurrently mutated genes. Genes 
significantly enriched for mutations predicted to have a functional impact on the 
encoded protein were identified using Bonferroni correction for multiple testing. 
Mutations observed in the 1,133 patients were analysed in isolation and in 
combination with published mutations in 2,347 trios with overlapping 
developmental disorders. Thirty-two candidate novel DD genes were modeled using 
morpholino knockdown in Zebrafish and morphological phenotyping over the first 
five days of development (Supplementary Table 6). 
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Tables 
 
Table 1 Breakdown of diagnoses by mode and by sex 
 Female (%) Male (%) Total (%) 
Undiagnosed 383 (69.6%) 433 (74.3%) 816 (72.0%) 
Diagnosed 167 (30.4%) 150 (25.7%) 317 (28.0%) 
De novo mutation 124 (22.5%) 80 (13.7%) 204 (18.0%) 
chrX 24 (4.4%) 5 (0.9%) 28 (2.6%) 
autosomal 100 (18.2%) 75 (12.9%) 176 (15.5%) 
Autosomal Dominant* 9 (1.6%) 11 (1.9%) 20 (1.8%) 
Autosomal Recessive 20 (3.6%) 26 (4.5%) 46 (4.1%) 
X-linked Inherited 1 (0.2%) 19 (3.3%) 20 (1.8%) 
UPD/Mosaicism 4 (0.7%) 6 (1.0%) 10 (0.9%) 
Composite 9 (1.6%) 8 (1.4%) 17 (1.5%) 
Total 550 583 1133 
 
* Inherited from an affected parent 
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Table 2 Novel genes with compelling evidence for a role in DD 
 
Evidence Gene 
de novos DDD 
(Missense, LoF) 
de novos Meta 
(Missense, LoF) 
P Value Test 
Mutation 
Clustering 
Predicted 
Haploinsufficiency 
De novo enrichment 
 
COL4A3BP 3 (3,0) 5 (5,0) 4.10E-12 Meta Yes 14.7% 
PPP2R5D 4 (4,0) 5 (5,0) 6.01E-12 DDD Yes 19.7% 
ADNP 4 (0,4) 5 (0,5) 4.59E-11 Meta No 9.8% 
POGZ 2 (0,2) 5 (0,5) 4.31E-10 Meta No 30.0% 
PPP2R1A 3 (3,0) 3 (3,0) 2.03E-08 DDD Yes 23.5% 
DDX3X 4 (3,1) 5 (3,2) 2.26E-07 DDD No 12.7% 
CHAMP1 2 (0,2) 3 (0,3) 4.58E-07 Meta No 52.9% 
BCL11A 3 (3,0) 4 (3,1) 1.03E-06 DDD Yes 0.6% 
PURA 3 (1,2) 3 (1,2) 1.14E-06 DDD No 9.4% 
       
De novo enrichment + 
additional evidence 
 
DNM1 3 (3,0) 5 (5,0) 1.43E-06 Meta No 13.5% 
TRIO 2 (2,0) 7 (7,0) 5.16E-06 Meta Yes 25.7% 
PCGF2 2 (2,0) 2 (2,0) 1.08E-05 DDD Yes 37.7% 
 
The table summarises the 12 genes with compelling evidence to be novel developmental disorder genes. The number of unrelated patients with independent functional or 
LoF mutations in the DDD cohort or the wider meta-analysis dataset including DDD patients is listed. The p value reported is the minimum p value from the testing of the 
DDD dataset and the meta-analysis dataset. The dataset that gave this minimal p value is also reported. Mutations are considered to be clustered if the p value of clustering 
of functional SNVs is less than 0.01. Predicted haploinsufficiency is reported as a percentile of all genes in the genome, with ~0% being highlight likely to be 
haploinsufficient and 100% very unlikely to be haploinsufficient, based on the prediction score described in Huang et al 
46
  updated to enable predictions for a higher 
fraction of genes in the genome. During submission, a paper was published online describing a novel developmental disorder caused by mutations in ADNP 
47
.  
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Table 3 Novel genes with suggestive evidence for a role in DD 
 
Evidence Gene 
de novos DDD 
(Missense, LoF) 
de novos Meta 
(Missense, LoF) 
P Value Test 
Mutation 
Clustering 
Predicted 
Haploinsufficiency 
De novo enrichment + 
additional evidence 
NAA15 1 (0,1) 3 (0,3) 1.64E-06 Meta No 7.5% 
ZBTB20 3 (1,2) 3 (1,2) 4.84E-06 DDD No 0.2% 
NAA10 2 (2,0) 3 (3,0) 8.28E-06 Meta No 34.1% 
TRIP12 3 (1,2) 4 (2,2) 2.13E-05 Meta No 3.8% 
USP9X 3 (1,2) 3 (1,2) 5.14E-05 DDD No 3.8% 
KAT6A 2 (0,2) 2 (0,2) 7.91E-05 DDD No 19.0% 
 
The table summarises 6 genes with suggestive evidence to be novel developmental disorder genes. The number of unrelated patients with independent functional or LoF 
mutations in the DDD cohort or the wider meta-analysis dataset including DDD patients is listed. The p value reported is the minimum p value from the testing of the DDD 
dataset and the meta-analysis dataset. The dataset that gave this minimal p value is also reported. Mutations are considered to be clustered if the p value of clustering of 
functional SNVs is less than 0.01. Predicted haploinsufficiency is reported as a percentile of all genes in the genome, with ~0% being highly likely to be haploinsufficient and 
100% very unlikely to be haploinsufficient, based on the prediction score described in Huang et al 
46
 updated to enable predictions for a higher fraction of genes in the 
genome.
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Table 4 Zebrafish modeling identifies 21 developmentally important candidate genes 
 
Gene  # patients Variant Patient phenotypes 
Phenotypic 
concordance 
Relevant knockdown phenotypes 
BTBD9 2/1 Biallelic LoF/De 
novo Missense 
Seizures, microcephaly, hypertonia Strong Reduced head size, brain volume 
CHD3 1/2 De novo 
LoF/Missense 
CNS and craniofacial defects Strong Abnormal head shape 
DDX3X 1/3 De novo 
LoF/Missense 
Moderately short stature, microcephaly, CNS defects Strong Reduced head size, brain volume 
ETF1 1 De novo LoF CNS and craniofacial defects, seizures, microcephaly, 
hypertelorism 
Strong Reduced head size, brain volume 
FRYL 1 De novo LoF Short stature, craniofacial and cardiac defects Strong Cardiac defects, reduced axis length 
PKN2 1 De novo Missense CNS, cardiac, ear, and craniofacial defects, growth 
retardation 
Strong Cardiac, craniofacial cartilage, and growth defects 
PSMD3 1 De novo Missense Microcephaly, muscular hypotonia, seizures, growth 
abnormality 
Strong Reduced head size and neural defects 
SCGN 1 Biallelic LoF Seizures, microcephaly, CNS defects Strong Reduced head size, brain volume 
SETD5 1 De novo LoF Seizures, CNS and cardiac defects, poor motor coordination Strong Reduced head size, cardiac defects, abnormal 
locomotion 
THNSL2 2 Biallelic LoF Microcephaly, CNS and  ear defects Strong Reduced head size, brain volume, neural defects 
ZRANB1 2 De novo Missense Microcephaly, muscle defects, seizures Strong Reduced head size and neural defects 
DPEP2 1 Biallelic LoF CNS defects, growth retardation Moderate Growth reduction 
PSD2 1 De novo LoF CNS defects, hypertonia, seizures Moderate Abnormal musculature, CNS and locomotion 
SAP130 1 De novo LoF Short stature, hypotonia, hypotelorism Moderate Abnormal locomotion 
CNOT1 1/1 De novo 
LoF/Missense 
Short stature, cardiac, CNS, ear and craniofacial defects Weak Multisystem 
DTWD2 1 De novo LoF CNS defects, seizures Weak Multisystem 
ILVBL 1 De novo LoF CNS and craniofacial defects Weak Multisystem 
NONO 1 De novo LoF CNS and ear defects, hypotonia, growth retardation Weak Multisystem, with otic and growth defects 
POGZ 2 De novo LoF CNS and ear defects, hypotonia, seizures, coloboma Weak Multisystem 
SMARCD1 1/1 De novo 
LoF/Missense 
CNS defects, hypotonia Weak Multisystem 
WWC1 1 De novo Missense CNS defects, hypertelorism None None 
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This table summarises the 21 genes whose knockdown results in developmental phenotypes in zebrafish. "# patients" column indicates how many patients were identified 
as carrying variants in these genes.  Split numbers indicate the breakdown of variant types (eg. for BTBD9, 2/1 is two biallelic LoF and one de novo missense carrying 
patients). A summary of the patient phenotypes is listed, as well as the relevant phenotypes observed in zebrafish knockdown experiments.  Phenotypic concordance 
categories indicate the degree of overlap between the zebrafish phenotyping and the patient phenotypes.  Weak concordance typically is the result of severe, multisystem 
phenotypes in zebrafish.  See Supplemental Materials for more detailed phenotype information. 
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Figure legends 
 
Figure 1 Expected and observed numbers of de novo mutations 
The expected and observed numbers of mutations of different functional 
consequences in three mutually exclusive sets of genes are shown, along with the p 
value from an assessment of a statistical excess of observed mutations. The three 
classes of genes are described in the main text. 
 
Figure 2 Excess of recurrently mutated genes 
Each panel shows the observed number of recurrently mutated genes (diamond) and 
the distribution of the number of recurrently mutated genes in 10,000 simluations 
(boxplot) under a model of no gene-specific enrichment of mutations: a. all protein-
altering mutations in all DDD children and undiagnosed DDD children, b. all LoF 
mutations in all DDD children and undiagnosed DDD children.  Each diamond is 
annotated with the median excess of recurrently mutated genes, with 95% 
confidence intervals in brackets. 
 
Figure 3 Gene-specific significance of enrichment for DNMs 
The –log10(p) value of testing for mutation enrichment is plotted only for each gene 
with at least one mutation in DDD children. On the X-axis is the p value of the most 
significant test in the DDD dataset, and on the Y-axis is the minimal p value from the 
significance testing in the meta-analysis dataset. Red indicates genes already known 
to be associated with developmental disorders (in DDG2P). Only genes with a p value 
of less than 0.05/18,272 (red lines) are labeled. 
 
Figure 4 Five novel genes with clustered mutations 
The domains (blue), post-translational modifications, and mutation locations (red 
stars) are shown for five proteins with highly clustered de novo mutations in 
unrelated children with severe, undiagnosed developmental disorders. For two 
proteins (COL4A3BP and PCGF2) where all observed mutations are identical, photos 
are shown to highlight the facial similarities of patients carrying the same mutation. 
 
Figure 5 Candidate gene Loss of Function modeling in zebrafish reveals enrichment 
for developmentally important proteins. 
a, Examples of developmental phenotypes: Knockdown of pkn2a results in reduced 
cartilaginous jaw structures (black arrows), knockdown of fryl results in cardiac and 
craniofacial defects (white arrowheads and arrows, respectively), while knockdown 
of psmd3 results in smaller ear primordia (red arrows), and mis-patterned CNS 
neurons (compare red double arrows and brackets).  b, Knockdown outcomes of 7 
genes with variants present in microcephaly patients: Interocular measurements of 
brightfield images from control and LoF embryos reveal significant decreases in head 
size.  A neuronal antibody stain (anti-HuC/D, green channel) labels the brains of 
control and morphant zebrafish.  Measurements taken across the widest extent of 
the midbrain identify significant reductions in brain size, likely underlying the 
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concomitant head size reductions seen in brightfield.  In b, tables show average 
percentage reduction in head and brain width, and p-values of a t-test. 
 
Figure 6 Saturation analysis for detecting haploinsufficient genes 
A boxplot showing the distribution of statistical power to detect a significant 
enrichment of LoF mutations across 18,272 genes in the genome, for different 
numbers of trios studied, from 1,000 trios to 12,000 trios. 
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Extended Data Tables (EDT) 
 
EDT1. Family History  
Self-declared family history (only first and second degree relatives recorded) 
 
EDT2. Consanguinity  
Self-declared versus consanguinity defined by identify by descent (IBD) 
 
EDT3. Biallelic Loss of function and damaging functional variants 
Rare (MAF < 5%) biallelic loss-of-function and damaging functional variants in 
uninherited diplotypes and probands. ‘Likely dominant probands’ refers to 
probands with a reported de novo mutation or affected parents, and ‘other 
probands’ to all remaining probands. ‘DDG2P Biallelic’ refers to confirmed and 
probable DDG2P genes with a biallelic mode of inheritance.  See Supplemental 
methods for details of variant processing. 
 
EDT4. Evidence of developmental role from animal models 
Concordant (‘C’) and Contradictory (‘D’) data from different animal models as to 
the developmental role of 21 genes showing a developmental phenotype in 
zebrafish knockdown experiments. 
a Damaging variant observed monoallelic (‘mono’) or biallelic (‘bi) in patients. 
b Concordance between phenotype in fish knockdown and patient 
c Results of different morpholinos targeting the same gene 
d Genome-wide significance (GWS) of mutation enrichment in patients 
e Summary of evidence across all organisms 
Extended Data Figures (EDF) 
 
EDF1. Gestation Adjusted Decimal Age at Last Clinical Assessment 
Histogram showing the distribution of the gestation adjusted decimal age at last 
clinical assessment across the 1133 probands. The dashed red line show the 
median age.  
 
EDF2. Log10 of the Frequency of HPO Term Usage 
Histogram showing the log10 of the number of times each HPO term was used 
within the 1133 proband patient records. 
 
EDF3.Projection PCA plot of the 1133 probands 
PCA plot of 1133 DDD probands projected onto a PCA analysis using 4 different 
HapMap population from the 1000 genomes project. Black: African, Red: 
European, Green: East Asian, Blue: South Asian and the 1133 DDD probands are 
represented by orange triangles.     
 
EDF4. Self Declared and Genetically Defined Consanguinity 
Overlaid histogram showing the distribution of kinship coefficients from KING 
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comparing parental samples for each trio. Green: Trios where consanguinity was 
not entered in the patient record on DECIPHER. Red: Trios consanguinity was 
declared in the patient record on DECIPHER. 
 
EDF5. Number of Validated de novo SNVs and indels per Proband 
Bar plot showing the distribution of the observed number of validated SNVs and 
indels per proband sample, and the expected distribution assuming a Poisson 
distribution with the same mean as the observed distribution. 
 
EDF6. Number of Diagnoses per Gene 
Histogram showing the number of diagnoses per gene for genes with at least two 
diagnoses from different proband samples. 
 
EDF7. Burden of Large CNVs in 1133 DDD Proband Samples 
Plot comparing the frequency of rare CNVs in three sample groups against CNV 
size. Y-axis is the on a log scale. Red: DDD probands who have not had previous 
microarray based genetic testing, Purple: DDD probands who have had negative 
previous microarray based genetic testing Green: DDD controls. 
 
EDF8. Candidate gene Loss of Function modeling in zebrafish identifies 
developmentally important genes and concordance with patient 
phenotypes. 
Each gene-specific panel includes a, patient information, including HPO terms, 
variant details (gene Ensembl id, inheritance, consequence, position and change 
in genome, transcript, and protein), b, zebrafish orthologue information 
including gene name, Ensembl gene id, morpholino sequence, knockdown 
confirmation assay, phenotypes relevant to those of patient, and concordance 
categories: Strong and Moderate concordance indicates specific phenotypes in 
animal models match those in the patient.  Weak concordance indicates poor 
overlap, often due to severe multisystem phenotypes. c lists standardized 
phenotypic observations in LoF zebrafish embryos, including MO dose, stage, 
affected tissue or behaviour (Entity) and effect (Quality).  Subsequent panels d-
m, display pairs of size and stage matched images of control and LoF zebrafish 
embryos, highlighting specific phenotypes where relevant. (See Supplemental 
methods for further details) 
 
BTBD9 
btbd9 knockdown embryos show reduced body size and cardiac edema (d versus 
e), and microcephalic changes including reduced head size (f,g versus i,j) and 
smaller brain (green channel, h versus k).  These head and CNS defects are 
concordant with the patient phenotypes. 
 
CHD3 
chd3 knockdown embryos display growth delays, including a smaller, 
abnormally shaped head and brain (f versus g), and curved body axis (d versus 
e).  The CNS defects strongly suggest concordance with the patient phenotypes. 
 
CNOT1 
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cnot1 knockdown embryos have numerous global developmental defects 
including a reduced body size at 24 hours (d versus e), malformed otic vescicle, 
and body axis curvature. 
 
DDX3X 
pl10 knockdown embryos show strong reductions in growth at higher MO doses 
(d versus e), and microcephalic changes in head size (f,g versus i,j) and a smaller 
brain (green channel, h versus k) at 2 days.  The microcephaly and CNS changes 
in morphant embryos are consistent with patient phenotypes reported. 
 
DPEP2 
dpep2 knockdown embryos show severe growth delays resulting in reduced 
body size, axis curvature and brain size (d versus e).   The reduced growth 
suggests possible concordance with the growth retardation reported for the 
patient. 
 
DTWD2 
dtwd2 knockdown embryos show lethal defects at high MO dose.  At lower doses, 
dtwd2 morphants have severe multisystem defects in head, brain, eye, somite 
and cardiac development resulting in dysmorphic embryos by day 2 (d versus e).  
The severity of these phenotypes precludes any assessment of concordance with 
the patient phenotypes(a versus c) 
 
ETF1 
At 6ng of etf1a MO, embryos show dramatic defects in early development 
including deformed notocord, somites, head, and CNS(d versus e).  At lower 
doses of MO, embryos show a milder set of defects that include microcephalic 
changes in head and brain size (h,i,j versus k,l,m) consistent with patient 
phenotypes. 
 
FRYL 
fryl MO injected embryos show decreased body length (b, relevant phenotypes), 
malformed cardiac structures, and an abnormal head size at day 2 (d,f versus 
e,g).  These are more pronounced at day 3, including craniofacial defects (h 
versus i, white arrows) and poor cardiac morphogenesis (j versus k, heart tissue 
in green channel).  These phenotypes are highly concordant with the presence of 
reduced stature, cardiac, and craniofacial phenotypes reported for the patient. 
 
ILVBL 
Embryos injected with 6ng of ilvbl MO display severe multisystem phenotypes 
including absence of trunk structures, small head and eyes, reduced 
pigmentation, with many embryos dying by day 2 (d versus e).   At lower doses, 
ilvbl morphants display brain edema, decreased body length, and a malformed 
head at 2 and 5 days (f,h versus g,i). The overlap of these severe zebrafish 
phenotypes with those of the patient is unclear, thus in weak concordance, 
despite an essential developmental role in the animal model. 
 
NONO 
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Embryos injected with nono MOs show severe multisystem developmental 
defects (d versus e), including abnormal somite segmentation, reduced body 
length, decreased CNS and spinal cord volume, a short thick trunk, and cardiac 
malformations.  Lower MO dosage reduces the severity of observed defects, 
while maintaining the complexity of the phenotype (c).  This complex LoF 
outcome cannot be correlated to the observed patient phenotypes and is thus in 
weak concordance. 
 
PKN2 
Zebrafish embryos injected with pkn2a morpholinos show progressively more 
severe development and growth defects, including abnormal cardiac outflow 
tract (f versus i, black arrows), thinner CNS with edema (g versus j), and 
reductions in craniofacial cartilage affecting jaw structures (h versus k, black 
arrows) in a dose dependent manner.  Reduced embryo length and head size 
reductions are apparent at days 2 and 3 (d,g versus e,j).  This phenotypic 
spectrum is strongly concordant with the cardiac, craniofacial, and growth 
defects reported for the patient. 
 
POGZ 
pogza MO injected embryos display a number of defects affecting brain, eye, ear, 
trunk, heart, and pigment development as well as overall growth retardation (d 
versus e).  This complex phenotype results in a weak concordance with the 
reported patient phenotypes. 
 
PSD2 
psd2a MO injected embryos have brain, trunk, heart and movements defects (c, 
and d versus e).  Although complex, at lower MO doses specific phenotypes of 
defective movement and abnormal head and brain development suggest a 
moderate concordance with patient phenotypes. 
 
PSMD3 
psmd3 MO injected zebrafish embryos show defects in trunk, and ear 
development (d,g versus e,j), microcephalic changes in head and brain size (f,h 
versus i,k), as well as aberrant neuronal patterning (h versus k, red double 
arrows and brackets) at day 2.  Overall, these phenotypes are strongly 
concordant with the described patient phenotypes. 
 
SAP130 
sap130 MO injected embryos display poor escape response to trunk touch 
stimuli at 2 days, and a failure to hatch from their chorions by day 5 (versus day 
2 in control embryos) likely due to decreased locomotion.  These movement 
defects are moderately concordant with the muscular phenotype in the patient's 
HPO terms. 
 
SCGN 
Embryos injected with scgn MOs show mildly reduced body size (d versus e), 
cardiac edema, and microcephalic changes including reduced head size (f,g 
versus i,j) and smaller brain (green channel, h versus k).  The zebrafish head and 
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brain phenotypes at all doses identify a strong concordance with the patient 
phenotypes. 
 
SETD5 
setd5 MO injected embryos display cardiac and head size defects at day 2 (f 
versus g), as abnormal escape response locomotion (see Supplemental video 
files).  These phenotypes are strongly concordant with the reported patient 
phenotypes (c  versus a). 
 
SMARCD1 
High dose smarcd1 MO injected embryos show severe phenotypes resulting in 
death by day 1.  At lower doses, embryos show severe multisystem phenotypes 
including CNS, trunk, and heart defects (d versus e, and c). 
 
THNSL2 
thnsl2 knockdown embryos show microcephalic changes including reduced head 
size (f,g versus i,j) and smaller brain (green channel, h versus k). These 
phenotypes are consistent with the observed patients' microcephaly and CNS 
defects. 
 
WWC1 
wwc1 MO injected embryos have defects in ear primordia development (reduced 
otolith number, d versus e) and an abnormal escape response at day 2.  These 
defects have no concordance with the patient phenotypes reported. 
 
ZRANB1 
Embryos co-injected with morpholinos for zranb1a and zranb1b display mild but 
significant reductions in head and brain size (f,g,h versus i,j,k, and b), consistent 
with the microcephaly and CNS defects present in both patients. 
 
 
EDF9. Distribution of haplinsufficiency scores in selected sets of de novo 
mutations  
Violin plot of haploinsufficiency scores in five sets of de novo mutations: Silent - 
all synonymous mutations, Diagnostic - mutations in known DD genes in 
diagnosed individuals, Undiagnosed_Func - all functional mutations in 
undiagnosed individuals, Undiagnosed_LoF - All LoF mutations in undiagnosed 
individuals, Undiagnosed_recur - mutations in genes with recurrent functional 
mutations in undiagnosed individuals. P values for a Mann-Whitney test 
comparing each of the latter four distributions to that observed for the silent 
(synonymous) variants are plotted at the top of each violin. 
Supplementary Data Tables (S) 
 
S1. HPO terms 
Human Phenotype Ontology terms used within the 1133 probands, where 
‘shallow_count’ is the number of time the specific term is used, and ‘deep_count’ 
is the number of times a term underneath that term in the ontology is used.  
 36 
 
S2. De novo mutations  
Validated de novo single nucleotide variants and indels within the 1133 
probands. Patient IDs have been removed to preserve patient confidentiality, but 
a file with linking IDs can be provided upon request subject to a data access 
agreement. Key: Chr – Chromosome; Pos – chromosome coordinate on GRCh37; 
Gene – HGNC symbol; Transcript – Ensemble transcript ID; Ref/Alt – Reference 
and Alternate alleles observed; Type – SNV or Indel; Consequence – Most severe 
consequence predicted by VEP across all transcripts for the gene; AAchange – 
amino-acid change using single letter codes; Regulatory – presence of the variant 
within one of the three classes of targeted regulatory sequence described in 
Supplementary Information; Validation – experimentally validated using an 
independent technology (‘DNM’) or not (‘Uncertain’); Diagnosis – variant is 
diagnostically pathogenic in a ‘Known’ or ‘Novel’ DD gene. 
 
S3. De novo CNVs  
De novo copy number variants within the 1133 probands detected using 
arrayCGH, exome sequencing or both. Patient IDs have been removed to 
preserve patient confidentiality, but a file with linking IDs can be provided upon 
request subject to a data access agreement. Key: Chr – Chromosome; Pos – 
approximate start chromosome coordinate on GRCh37;End – approximate end 
chromosome coordinate on GRCh37; Ref – reference base at start position; Alt – 
Deletion ‘<DEL>’ or Duplication ‘<DUP>’; Call_source – called from exome data, 
aCGH data, or both; copy_number – estimated copy number: ‘1’ – heterozygous 
deletion, ‘3’ – heterozygous duplication, ‘.’ uncertain copy number; w_score - 
confidence metric from aCGH analysis, larger is more confident; convex_score – 
confidence metric from exome analysis, larger is more confident; consequence - 
Most severe consequence predicted by VEP across all transcripts; Transcript – 
Ensembl transcript in which most severe consequence was observed; Gene – 
HGNC symbol in which most severe consequence was observed; Genes – all 
genes encompassed by the CNV. 
 
S4. Diagnoses  
All diagnostic variants, in both known and new genes, with links to the patient ID 
in DECIPHER. Key: DECIPHER_ID – ID in DECIPHER; Sex – Male or Female; 
Fam_Hist - Relatives with similar phenotypes; Chr - chromosome; Start - start 
chromosome coordinate on GRCh37; Stop - end chromosome coordinate on 
GRCh37; Gene – HGNC symbol; Gene_type – known or novel DD gene; 
Variant_type – class of variant; Genotype – heterozygous, homozygous, 
compound heterozygous, hemizygous, or type of UPD, or clonality of mosaicism; 
Ref/Alt – reference and alternate alleles observed; Consequence – predicted 
consequence on affected gene(s); Inheritance – de novo or inherited from 
mother, father, or both; Phenotypes – HP terms observed in proband. 
 
S5. Biallelic loss-of-function variant counts   
Biallelic, rare (MAF < 5%), loss-of-function variant counts for probands and 
uninherited diplotypes.  See supplemental methods for details of variant 
processing.  Patient IDs have been removed to preserve patient confidentiality, 
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but a file with linking IDs can be provided upon request subject to a data access 
agreement. 
 
S6. Morpholinos and Primers  
Both human and zebrafish gene names are listed, as well as Ensembl gene reference 
ids. For each gene, Decipher ids are listed for all patients carrying variants. The 
Variant column indicates type of variant, and number of probands with each type. 
Zebrafish phenotype indicates whether a developmental phenotype was detected 
upon gene knockdown. Double KD indicates that phenotypes were only seen with 
co-knockdown of both zebrafish orthologues. Morpholino sequence is listed as 
synthesised (orientation is antisense to RNA transcript). Where feasible, primers 
were selected to detect aberrant splicing in cDNA from injected embryos (Primer 
Sequences). Translation initiation/ATG blocking morpholinos do not affect mRNA 
splicing, therefore their activity cannot be detected by RT-PCRs (primers labeled 
N/A). ND indicates primers were not selected for these genes. For a subset of genes, 
a second replication morpholino was designed (Morpholino 2 Sequence). See 
Supplemental methods for additional details. 
 
S7. Zebrafish genes and phenotypes table 
Standardised phenotype ontological description for all genes showing 
developmental roles in zebrafish knockdown experiments. All knockdown 
animals were observed in comparison to control injected animals, and all 
morphological and locomotor defects were recorded in entity/quality format6. 
Dose indicates morpholino level relative to range injected in each experiment, 
Amount gives specific dose injected in nanograms per embryo.  See Supplemental 
methods for additional details. 
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